Choice of Antimicrobial Therapy

A. Empiric Therapy:
Prior to receiving specific susceptibility results, drugs to which organisms are greater than 80% susceptible are generally considered good choices, although patient history, site of infection, and specific pharmacologic properties as they apply to the particular patient must be taken into account.

B. Therapeutic Therapy:
The drug of choice for treatment of an infection is usually the most active drug against the pathogenic organism or the organism most likely to cause infection. Choice of drugs should be modified by site of infection and patient's clinical status regarding allergy, renal function, immune status or pregnancy.

Visit us on the Web
www.laboratoryalliance.com

Organism	Number of Isolates*	Ampicillin	Amoxicillin/clavulanate**	Piperacillin/tazobactam	Cephalothin	Cefazolin	Cefoxitin	Cefuroxime	Cefpodoxime	Cefepime	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Ciprofloxacin	Levofloxacin	Moxifloxacin	Norfloxacin	Gentamicin#	Tobramycin	Amikacin	Tetracycline (Doxycycline)	Trimethoprim/sulfamethoxazole (Bactrim)	Nitrofurantoin	Clindamycin	Erythromycin	Azithromycin	Oxacillin***	Penicillin	Vancomycin	Rifampin#	Gentamicin-Synergy
ESCHERICHIA COLI	5572	60	82	96	61	92	92	86	98	99	99	99	100	100	100	81	80	88	80	92	94	100	82	83	95								
KLEBSIELLA PNEUMONIAE	1067	0	96	97	93	97	94	91	98	99	99	99	99	94	93	97	97	98	98	99	99	95	88	92	32								
PROTEUS MIRABILIS	616	84	100	100	90	96	97	96	99	99	99	99	100	100	100	78	78	93	79	97	98	99	0	81	0								
ENTEROBACTER CLOACAE	286	0	0	88	0	0	1	0	2	98	88	89	100	100	100	95	94	98	95	96	97	100	82	84	30								
CITROBACTER FREUNDII	177	0	0	93	0	0	3	71	3	100	94	94	100	100	100	91	90	100	94	95	98	100	83	85	91								
KLEBSIELLA OXYTOCA	157	0	90	92	85	73	97	88	98	100	100	100	100	100	100	99	98	100	100	99	99	100	97	97	73								
SERRATIA MARCESCENS	117	0	0	100	0	0	23	0	0	100	100	100	100	100	100	98	100	NI	100	100	98	100	28	98	0								
CITROBACTER KOSERI	95	0	0	95	90	100	95	68	99	100	100	100	100	100	100	98	97	NI	100	100	100	100	99	100	69								
MORGANELLA MORGANII	78	0	0	76	0	0	37	0	0	96	87	96	100	100	100	76	76	NI	79	96	100	100	0	77	0								
ENTEROBACTER AEROGENES	77	0	0	93	0	0	0	75	0	100	94	96	100	100	100	96	95	NI	95	100	100	100	97	99	13								
PSEUDOMONAS AERUGINOSA	864			94						92	94	NI$		90	92	77	64	NI		82	96	97	100									
ENTEROCOCCUS SP., VSE	1109	98														69	70						19		97						100		72
ENTEROCOCCUS SP., VRE	53	21														0	0						20		27						0		75
STAPH. AUREUS, MSSA	2003															92	93	96		100			96	99	98	75	65		100	0	100	100	
STAPH. AUREUS, MRSA	1098															43	43	0		100			97	99	99	75	13		0	0	100	100	
STAPH. SPECIES, COAG.NEG	799															51	52	70		93			81	69	98	61	42		48	0	99	99	
HAEM INFLUENZAE COMM WIDE	170	66						90				100				91	91	99					99	68				96					
STREP PNEUMONIAE COMM WIDE	177											91			86		98	99					83	83		88	66	66		63/88##	100		

(Data are % Susceptible)

* Note: isolates are from all sources; urine, blood, respiratory, wound, etc.

** AMOX/CLAV PREDICTS AMP/SULBAC

*** Oxacillin susceptible Staph are also susceptible to other penicillinase resistant penicillins, betalactam/betalactamase inhibitor combinations, cephems, and carbapenems FDA approved to treat Staph infections.

Gentamicin and Rifampin may be used in combination with other drugs against Staph isolates.

88% were in the intermediate or susceptible range indicating those could be treated for pneumonia with appropriate dosing of an IV penicillin.

$ NI= drug not active

The percentage in red are greater than or equal to 80% susceptibility, potentially useful for empiric therapy.

Contact Us

Customer Service:
(315) 461-3008

RRL at Community General:
(315) 492-5531

RRL at Crouse Hospital:
(315) 470-7391

RRL at St. Joseph's Hospital:
(315) 448-5400

www.laboratoryalliance.com

Visit us on the Web
www.laboratoryalliance.com

LABORATORY ALLIANCE
of Central New York, LLC
Operations Center
113 Innovation Lane • Liverpool, New York 13088
Ph: (315) 410-7000 • Fax (315) 410-7007

2011
OUT-PATIENT ANTIBIOGRAM

Data are Percent Susceptible
Jan. 2010 – Dec. 2010

Michael R. O'Leary, MD, Medical Director
Paul A. Granato, PhD, Director, Microbiology
Russell A. Rawling, MS, Microbiology Manager